Jove
Visualize
联系我们

相关概念视频

Positron Emission Tomography01:29

Positron Emission Tomography

6.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.8K
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  3. 前列腺特异性膜抗原pet-ct在治疗目的手术或放射治疗前的高风险前列腺癌患者:前性随机多中心研究
  1. 首页
  3. 前列腺特异性膜抗原pet-ct在治疗目的手术或放射治疗前的高风险前列腺癌患者:前性随机多中心研究

相关实验视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

前列腺特异性膜抗原PET-CT在治疗目的手术或放射治疗前的高风险前列腺癌患者:前性随机多中心研究

Michael S Hofman1, Nathan Lawrentschuk2, Roslyn J Francis3

  • 1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Lancet (London, England)
|March 27, 2020

在PubMed 上查看摘要

概括
此摘要是机器生成的。

与传统成像相比,前列腺特异性膜抗原 (PSMA) PET-CT 提供了更高的准确性来确定高风险前列腺癌的阶段. 这种新的方法改善了转移性疾病的检测,并影响了患者的治疗决策.

更多相关视频

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

558
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

相关实验视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

558
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

科学领域:

  • 癌症学
  • 放射学
  • 核医学

背景情况:

  • 传统的成像 (CT和骨扫描) 对高风险局部前列腺癌的男性的分期敏感性有限.
  • 需要更准确的成像技术来指导这些患者的治疗决策.

研究的目的:

  • 调查前列腺特异性膜抗原 (PSMA) PET-CT与常规成像测定高风险前列腺癌男性的准确性.
  • 与标准成像方案相比,确定PSMA PET-CT是否会影响患者的治疗.

主要方法:

  • 一项多中心的随机研究,涉及302名高风险前列腺癌患者.
  • 患者被分配到传统的成像 (CT和骨扫描) 或-68 PSMA-11 PET- CT.
  • 通过将结果与参考标准进行比较来评估成像准确性,包括6个月后的细胞病理学,成像学和生物化学学.

主要成果:

  • 在识别骨盆结节或远程转移性疾病方面,PSMA PET-CT显示出明显更高的准确性 (92%),而不是传统成像 (65%).
  • PSMA PET-CT显示出更高的灵敏度和特异性,导致更频繁的管理变化 (28%与15%).
  • 传统的成像导致更高的辐射暴露 (19.2 mSv与8.4 mSv) 和更多的模两可的发现.

结论:

  • PSMA PET-CT是一种优越的成像方法,用于分期高风险的前列腺癌,其性能优于传统的CT和骨扫描.
  • 提高PSMA PET-CT的准确性有助于更明智的管理决策,并减少模两可的发现.
  • 在这种患者群体中,PSMA PET-CT可被认为是传统成像的合适替代品.